In a report released today, Yang Huang from Merrill Lynch maintained a Buy rating on BeiGene (BGNE), with a price target of $230.00. The company’s shares closed last Monday at $198.25, close to its 52-week high of $204.00.
Huang has an average return of 43.1% when recommending BeiGene.
According to TipRanks.com, Huang is ranked #2570 out of 5679 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeiGene with a $219.71 average price target, an 8.7% upside from current levels. In a report issued on November 3, J.P. Morgan also maintained a Buy rating on the stock with a $215.00 price target.
See today’s analyst top recommended stocks >>
Based on BeiGene’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $85.43 million. In comparison, last year the company had a GAAP net loss of $143 million.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BGNE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).
